KRAS and colorectal carcinoma: In the present study we have investigated the mechanisms that eventually lead to resistance to the vertical suppression of MAPK pathway through combination of EGFR and MEK inhibition in a cellular model of primary resistance to anti-EGFR therapy constituted by KRAS mutated CRC cell lines.